Simulations Plus (SLP) Downgraded to Buy at BidaskClub
BidaskClub downgraded shares of Simulations Plus (NASDAQ:SLP) from a strong-buy rating to a buy rating in a research note published on Thursday morning.
Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Simulations Plus from a hold rating to a buy rating and set a $21.00 price objective for the company in a research report on Thursday, May 17th. ValuEngine cut Simulations Plus from a strong-buy rating to a buy rating in a research report on Wednesday, July 11th.
Simulations Plus stock opened at $20.49 on Thursday. The company has a market capitalization of $349.91 million, a PE ratio of 60.26 and a beta of -0.85. Simulations Plus has a 12 month low of $14.10 and a 12 month high of $23.95.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 2nd. Stockholders of record on Thursday, July 26th were given a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date was Wednesday, July 25th. Simulations Plus’s dividend payout ratio (DPR) is presently 70.59%.
In other news, Chairman Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $20.33, for a total value of $376,105.00. Following the completion of the sale, the chairman now directly owns 5,436,408 shares in the company, valued at $110,522,174.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 33.45% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. boosted its stake in shares of Simulations Plus by 16.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 22,688 shares of the technology company’s stock worth $505,000 after acquiring an additional 3,188 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Simulations Plus by 27.4% in the fourth quarter. Deutsche Bank AG now owns 24,583 shares of the technology company’s stock worth $394,000 after acquiring an additional 5,282 shares during the last quarter. MetLife Investment Advisors LLC acquired a new stake in shares of Simulations Plus in the second quarter worth approximately $129,000. Raymond James & Associates boosted its stake in shares of Simulations Plus by 14.5% in the second quarter. Raymond James & Associates now owns 49,615 shares of the technology company’s stock worth $1,104,000 after acquiring an additional 6,267 shares during the last quarter. Finally, Stanley Laman Group Ltd. boosted its stake in shares of Simulations Plus by 11.0% in the second quarter. Stanley Laman Group Ltd. now owns 68,585 shares of the technology company’s stock worth $1,526,000 after acquiring an additional 6,812 shares during the last quarter. 35.91% of the stock is currently owned by hedge funds and other institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Further Reading: Are analyst ratings accurate?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.